Novo Nordisk Seeks Preliminary Injunction in Lanham Act Lawsuit Against Eli Lilly Over "Outdated" Comparative Ads
The high-stakes legal battle between the two giants of the GLP-1 obesity market, Novo Nordisk and Eli Lilly, has intensified with a scheduled federal court hearing on August 27, 2026. A federal judge in Trenton, New Jersey, will consider Novo Nordisk's motion for a preliminary injunction to immediately halt Eli Lilly's nationwide comparative advertising campaigns for its blockbuster drugs, Zepbound and Mounjaro.
The legal dispute began on July 21, 2026, when Novo Nordisk filed a federal lawsuit in the U.S. District Court for the District of New Jersey, alleging that Eli Lilly violated the Lanham Act and state false advertising and unfair competition laws.1 The core of Novo's complaint is that Eli Lilly's direct-to-consumer commercials and ads mislead patients by comparing the highest doses of Lilly's tirzepatide drugs (15 mg) against lower, outdated doses of Novo's semaglutide products (1.7 mg or 2.4 mg for Wegovy; 1 mg for Ozempic), rather than Novo's newer and more potent doses.
Specifically, Novo argues that Lilly’s television advertisements compare Zepbound to Wegovy using data from the SURMOUNT-5 clinical trial while omitting critical context: Novo's higher-dose 7.2 mg Wegovy injection was approved by the FDA in March 2026, and clinical data from the STEP UP trial indicates comparable efficacy. Furthermore, Novo accuses Lilly of comparing Mounjaro’s maximum 15 mg dose to Ozempic’s lower 1 mg dose, ignoring Ozempic's approved 2 mg maintenance dose. While Lilly includes footnotes referencing the higher Wegovy and Ozempic doses, Novo claims these fine-print disclosures are legally insufficient to correct the overall deceptive impression.
Eli Lilly has vigorously defended its marketing, maintaining that its ads are truthful and based on the gold standard of clinical evidence—specifically, SURMOUNT-5, which remains the only completed randomized, head-to-head trial comparing tirzepatide and semaglutide directly.
What It Means for Investors
This Lanham Act litigation represents a critical battleground for market share in the $80 billion GLP-1 space. While the lawsuit does not threaten drug approvals or labeling, a preliminary injunction would force Eli Lilly to immediately pull its highly successful comparative ad campaigns and potentially run corrective messaging. This could blunt Lilly's marketing momentum, which has allowed Zepbound to rapidly capture market share from Wegovy. Conversely, if the judge denies the injunction on August 27, it will validate Lilly's aggressive comparative marketing strategy and keep Novo on the defensive.
Verbatim Quotes
- John F. Kuckelman, Senior VP and Group General Counsel at Novo Nordisk:
"Healthcare companies have a responsibility to keep their public claims accurate and current — ineffective, fine-print disclaimers do not fix the misleading impression created by major national campaigns." — NBC New York Article
- Eli Lilly Spokesperson Statement:
"Rather than compete on the merits of its products, Novo is asking a court to stop Lilly from communicating the results of that trial." — Reuters Article
-
An instance of Blockbuster metabolic exclusivity is decided in the courtroom rather than the clinic. — Top pharmaceutical giants are using aggressive Lanham Act litigation over comparative advertising campaigns to protect their market share in court. ↩︎